Vertex Pharmaceuticals (VRTX) Goodwill & Intangibles (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Goodwill & Intangibles of $1.5 billion for Q1 2026, down 1.48% year-over-year from $1.5 billion in Q1 2025, and little changed quarter-over-quarter from $1.5 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Goodwill & Intangibles history runs 18 years deep, the most recent figure standing at $1.5 billion for Q1 2026.
- In Q1 2026, Goodwill & Intangibles fell 1.48% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (down 1.48% YoY), while the FY2025 annual figure was $1.5 billion, down 20.99% from the prior year.
- Goodwill & Intangibles for Q1 2026 stood at $1.5 billion, roughly flat from $1.5 billion in the prior quarter.
- The five-year high for Goodwill & Intangibles was $1.9 billion in Q4 2023, with the low at $1.4 billion in Q2 2022.
- The 5-year median for Goodwill & Intangibles is $1.7 billion (2022), against an average of $1.7 billion.
- The sharpest annual moves came in 2023 and 2025: Goodwill & Intangibles advanced 21.77% in 2023, then retreated 20.99% in 2025.
- Vertex Pharmaceuticals' Goodwill & Intangibles stood at $1.7 billion in 2022, then advanced by 14.68% to $1.9 billion in 2023, then slipped by 1.34% to $1.9 billion in 2024, then declined by 20.99% to $1.5 billion in 2025, then decreased by 0.38% to $1.5 billion in 2026.
- Business Quant data shows VRTX's Goodwill & Intangibles at $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Bn |
| Mar 31, 2026 | 1.51 Bn |
| Dec 31, 2025 | 1.51 Bn |
| Sep 30, 2025 | 1.52 Bn |
| Jun 30, 2025 | 1.52 Bn |
| Mar 31, 2025 | 1.53 Bn |
| Dec 31, 2024 | 1.91 Bn |
| Sep 30, 2024 | 1.92 Bn |
| Jun 30, 2024 | 1.93 Bn |
| Mar 31, 2024 | 1.92 Bn |
| Dec 31, 2023 | 1.94 Bn |
| Sep 30, 2023 | 1.69 Bn |
| Jun 30, 2023 | 1.69 Bn |
| Mar 31, 2023 | 1.69 Bn |
| Dec 31, 2022 | 1.69 Bn |
| Sep 30, 2022 | 1.68 Bn |
| Jun 30, 2022 | 1.39 Bn |
| Mar 31, 2022 | 1.40 Bn |
| Dec 31, 2021 | 1.40 Bn |
| Sep 30, 2021 | 1.40 Bn |